Introducing Veroplex™

Ology Bioservices’ Proprietary Vero Cell PlatformNeed an established and validated platform to manufacture your vaccine candidate? Look no further than Ology Bio’s proprietary Veroplex Platform, comprised of proven Vero cells, patented processes for vaccine development and production, and experienced regulatory support.

• Reliable, stable, and proven high-yieldworking cell banks (WCBs)

• WCB passage number as low as 133

• Adapted to grow in serum-free media, andfor growth on 60-250 micron microcarriers

• Consistent density, viability and productionduring scale-up from 15L to 6000L bioreactors

• Extensive regulatory documentation and expertsupport, DMF 10336

• Accepted by regulatory authorities in more than60 countries

1. Vero Cell Propagation

2. Virus Replication

3. Harvesting and Inactivation

4. Purification

Each step is well established and standardized in the Veroplex Platform and can be manufactured in Ology Bio’s BSL-3 capable manufacturing facility.

Vero Cells on Microcarriers

Vero Cells Preinfection

Vero Cells 2-3 Days Post Infection

Capable. Collaborative. Creative.

TM

Veroplex Cells

Veroplex Patented Processes

13200 NW Nano Court | Alachua, FL 32615 | T. 386-462-9663 | F. 386-462-2087 | ologybio.com

TM

A Streamlined Manufacturing Process for Inactivated Viral Vaccines

Virus Propagation

Fermentation (Fermenter 1-3)

Cell Harvesting (Separator)

Vero CellInoculum

Production Virus Bank

Vero Working Cell Bank

Working Virus Bank

Vero Master Cell Bank

Seed Virus Bank

Benzonase Incubation

DoubleInactivation

Purification I (Ultracentrifugation)

Purification II (Ultra/Diafiltration,

Benzonase Incubation)

Inactivated Whole Virus Vaccine Drug Substance

Superior Manufacturing with Veroplex™

Ology Bio™ offers CDMO clients manufacturing licenses to the well-established and validated technology.